In this research study, we are looking at the anti-tumor effects of Cabozantinib (XL184) in
metastatic breast cancer. Data suggest that MET expression and activation are important for
initiation and progression of triple-negative breast cancer (TNBC). We evaluated the efficacy
of cabozantinib (XL184), a novel inhibitor of multiple receptor tyrosine kinases, including
MET and VEGFR2, in patients with metastatic TNBC.